New pill plus immunotherapy shows promise in early cancer trial
NCT ID NCT04344795
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study tested an experimental drug called TPST-1495, taken as a pill, either alone or combined with the immunotherapy Keytruda (pembrolizumab). The trial included 89 people with advanced solid tumors like colorectal, lung, head and neck, and endometrial cancers who had run out of standard options. The main goal was to find the safest dose and check for any signs that the drugs can control tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TPST-1495 (an experimental drug taken by mouth) and pembrolizumab (Keytruda, an immunotherapy given by IV)
What this could lead to
If this works, it could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early, first-in-human trial with only 89 participants. The drug may not shrink tumors or could cause side effects. Success in this small study does not guarantee it will work in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baystate Gynecologic Oncology
Springfield, Massachusetts, 01107, United States
-
Carolina BioOncology Institute
Huntersville, North Carolina, 28078, United States
-
SCRI-OK Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine
Baltimore, Maryland, 21287, United States
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States